Clinical tests of the novel small-molecule inhibitor of p38α MAPK, VX-702 ... a role in inflammation by mediating the cellular response to stress, pathogens, and cytokines.

(C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated with MEK inhibitor–containing treatment regimens. (E) PFS and (F) OS in patients who experienced a response to MAPK ...

Previous research has indicated that MAPK inhibitors could be a potential therapy for NRAS MUT melanoma. However, on their own, MAPK inhibitors fail in about 80% of cases and don't extend patient ...

In particular, I explore pharmacological targeting and characterization of upstream-driven feedbacks of MAPK pathway. I study and characterize the response to KRAS G12C, SOS1 and SHP2 inhibitors alone ...

MAPK pathway inhibitors are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as ...